Cure My Disease

Don't miss your cure!

 Log in / Sign up

HIV prevention shot under Long-Term watch in 3,500 volunteers

NCT ID NCT06134362

Ongoing Prevention Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study is checking the long-term safety and effectiveness of a long-acting injectable drug called cabotegravir (CAB LA) for preventing HIV. It includes about 3,500 people who already received CAB LA in earlier HIV prevention studies. Participants will continue getting the shots and be monitored for new HIV infections, serious side effects, and injection site reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

  • GSK Investigational Site

    Almagro, C1427CEA, Argentina

  • GSK Investigational Site

    Buenos Aires, 1221, Argentina

  • GSK Investigational Site

    Francistown, Botswana

  • GSK Investigational Site

    Porto Alegre, 91350-200, Brazil

  • GSK Investigational Site

    Rio de Janeiro, 21040-360, Brazil

  • GSK Investigational Site

    São Paulo, 04121-000, Brazil

  • GSK Investigational Site

    São Paulo, 05403-000, Brazil

  • GSK Investigational Site

    Mbabane, H103, Eswatini

  • GSK Investigational Site

    Kisumu, 40100, Kenya

  • GSK Investigational Site

    Blantyre, Malawi

  • GSK Investigational Site

    Lilongwe, CLW, Malawi

  • GSK Investigational Site

    Lima, 15001, Peru

  • GSK Investigational Site

    Lima, 15024, Peru

  • GSK Investigational Site

    Lima, 15088, Peru

  • GSK Investigational Site

    Lima, Lima 04, Peru

  • GSK Investigational Site

    Piura, 20000, Peru

  • GSK Investigational Site

    Cape Town, 7505, South Africa

  • GSK Investigational Site

    City of Cape Town, 755, South Africa

  • GSK Investigational Site

    City of Cape Town, 792, South Africa

  • GSK Investigational Site

    City of Johannesburg, 2001, South Africa

  • GSK Investigational Site

    Durban, 4110, South Africa

  • GSK Investigational Site

    Durban, 4400, South Africa

  • GSK Investigational Site

    Isipingo, 4110, South Africa

  • GSK Investigational Site

    Sol Plaatjie, 8301, South Africa

  • GSK Investigational Site

    Chiang Mai, Chiang Mai, 50200, Thailand

  • GSK Investigational Site

    Pathum Wan, 10330, Thailand

  • GSK Investigational Site

    Entebbe, 49, Uganda

  • GSK Investigational Site

    Kampala, Uganda

  • GSK Investigational Site

    Hanoi, Vietnam

  • GSK Investigational Site

    Chitungwiza, 00263, Zimbabwe

  • GSK Investigational Site

    Chitungwiza, 230221, Zimbabwe

  • GSK Investigational Site

    Chitungwiza, 263, Zimbabwe

  • GSK Investigational Site

    Harare, Zimbabwe

More trials for these conditions

Other studies related to the condition(s) this trial covers.